Accéder au contenu
Merck
Toutes les photos(1)

Documents

EZHS40

Millipore

Human Amyloid β40 ELISA Kit

measures and quantifies Amyloid β40 levels in 50 μL CSF, cell culture supernatent or plasma

Synonyme(s) :

Amyloid-beta protein 40

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Code UNSPSC :
12161503
eCl@ss :
32161000
Nomenclature NACRES :
NA.84

product name

High Sensitivity Human Amyloid β40 ELISA, This High Sensitivity Human Amyloid β40 ELISA is used to measure & quantify Amyloid β40 levels in Neuroscience research.

Niveau de qualité

Espèces réactives

human

Conditionnement

kit of 1 × 96 wells

Paramètres

50 μL sample volume (Overnight assay)

assay range

sensitivity: 6.0 pg/mL
(50 μl sample size)

standard curve range: 16-500 pg/mL

Technique(s)

ELISA: suitable

Entrée

sample type plasma (K2 EDTA)
sample type serum
sample type cerebrospinal fluid (CSF)

Application(s)

research use

Méthode de détection

colorimetric (450nm/590nm)

Conditions d'expédition

wet ice

Température de stockage

2-8°C

Informations sur le gène

human ... APP(351)

Description générale

Amyloid beta peptides have been implicated in the etiology of Alzheimer’s disease. Amyloid beta 40 is the most prominent peptide and Amyloid beta 42 is the neurotoxic form. The Amyloid beta 42/40-ratio (AB ratio) has been reported as a better indicator of the Alzheimer pathology. Millipore’s High Sensitivity Human Amyloid β40 ELISA kit is used for the measurement of Amyloid β40 in cerebrospinal fluid, cell culture supernatants, primary neurons and plasma in a 96-well format.

Spécificité

The Amyloid β40 ELISA (HS) uses monoclonal anti-Aβ antibodies with high selectivity for human Aβ. The capture antibody recognizes the C-terminal end of Amyloid β1-40, which causes a high selectivity for Aβ 40. The cross-reactivity of the used antibodies to other Amyloid peptides was tested by ELISA and BIACORE and shows no significant cross-reactivity to Aβ1-38, Aβ1-39, Aβ1-42, Aβ1-43 and Aβ1-44.

Application

Research Category
Neuroscience
Research Sub Category
Alzheimer′s Disease
This High Sensitivity Human Amyloid β40 ELISA is used to measure & quantify Amyloid β40 levels in Neuroscience research.
This assay requires 50 µl of sample (cerebrospinal fluid, cell culture supernatants, primary neurons, or plasma) and is an overnight assay.
Used to detect/quantify: Amyloid β40

Stockage et stabilité

Components in the kit can be stored up to 2 weeks at 2-8°C

Autres remarques

Please contact Technical Service for linearity of dilution.

Clause de non-responsabilité

For research use only. Not for use in diagnostic procedures.

Pictogrammes

CorrosionExclamation mark

Mention d'avertissement

Warning

Mentions de danger

Classification des risques

Aquatic Chronic 3 - Met. Corr. 1 - Skin Sens. 1

Code de la classe de stockage

8A - Combustible corrosive hazardous materials


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Gunjan Manocha et al.
Current Alzheimer research, 15(12), 1123-1135 (2018-08-03)
Alzheimer's disease (AD) is associated with age-associated central nervous system degeneration and dementia. This decline in the function correlates with deposition of Aβ peptide containing plaques and associated reactive gliosis. The inflammatory phenotype of microglia, in particular, is often considered
Nataliya Golovyashkina et al.
Molecular neurodegeneration, 10, 60-60 (2015-11-07)
Dendritic simplification, a key feature of the neurodegenerative triad of Alzheimer's disease (AD) in addition to spine changes and neuron loss, occurs in a region-specific manner. However, it is unknown how changes in dendritic complexity are mediated and how they
Anna Bogstedt et al.
Journal of Alzheimer's disease : JAD, 46(4), 1091-1101 (2015-09-25)
Utilizing decision making biomarkers in drug development requires thorough assay validation. Special considerations need to be taken into account when monitoring biomarkers using immunoassays in the presence of therapeutic antibodies. We have developed robust and sensitive assays to assess target
Kendra L Puig et al.
Journal of Alzheimer's disease : JAD, 44(4), 1263-1278 (2014-11-20)
Alzheimer's disease (AD) is a neurodegenerative disorder histologically characterized by amyloid-β (Aβ) protein accumulation and activation of associated microglia. Although these features are well described in the central nervous system, the process and consequences of Aβ accumulation in the enteric
Angela M Floden et al.
Current Alzheimer research, 17(12), 1133-1144 (2021-01-20)
Beta amyloid (Aβ) peptide containing plaque aggregations in the brain are a hallmark of Alzheimer's Disease (AD). However, Aβ is produced by cell types outside of the brain suggesting that the peptide may serve a broad physiologic purpose. Based upon

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique